SCHEMBL5658441

SCHEMBL5658441

COc1c(C)cc(C2(c3ccc(NC(C)=O)cc3)C(=O)N(Cc3ccccc3Cl)c3ccccc32)cc1C

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.49
TP53 P04637 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 2/20 0.43
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43
HTT P42858 1/20 0.43
POLB P06746 2/20 0.41
RAB9A P51151 2/20 0.39
CNR1 P21554 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
EDNRB P24530 1/20 0.38
EDNRA P25101 1/20 0.38
SCN9A Q15858 2/20 0.38
NPSR1 Q6W5P4 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659557 0.91 TP53 (0.45) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5658475 0.87 MAPT (0.46) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5660886 0.86 MAPT (0.49) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5659749 0.84 MAPT (0.51) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5658322 0.83 MAPT (0.47) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5660556 0.81 MAPT (0.46) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5659083 0.79 MAPT (0.58) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5659726 0.79 TP53 (0.52) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL14457600 0.78 MAPT (0.44) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5660174 0.78 CNR1 (0.57) MAPTTP53SMN1; SMN2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 MAPT 3588/4885TP53 3370/4885SMN1; SMN2 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.